ofloxacin has been researched along with Colorectal Neoplasms in 3 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combination of cholestyramine/levofloxacin is a promising option for the prevention of delayed diarrhea caused by irinotecan." | 9.12 | Phase II clinical trial for prevention of delayed diarrhea with cholestyramine/levofloxacin in the second-line treatment with irinotecan biweekly in patients with metastatic colorectal carcinoma. ( Fischbach, W; Flieger, D; Hainke, S; Keller, R; Klassert, C; Kleinschmidt, R, 2007) |
| "The combination of cholestyramine/levofloxacin is a promising option for the prevention of delayed diarrhea caused by irinotecan." | 5.12 | Phase II clinical trial for prevention of delayed diarrhea with cholestyramine/levofloxacin in the second-line treatment with irinotecan biweekly in patients with metastatic colorectal carcinoma. ( Fischbach, W; Flieger, D; Hainke, S; Keller, R; Klassert, C; Kleinschmidt, R, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Marcelo, GA | 1 |
| Galhano, J | 1 |
| Robalo, TT | 1 |
| Cruz, MM | 1 |
| Marcos, MD | 1 |
| Martínez-Máñez, R | 1 |
| Duarte, MP | 1 |
| Capelo-Martínez, JL | 1 |
| Lodeiro, C | 1 |
| Oliveira, E | 1 |
| Lorenzo Garde, L | 1 |
| Bolaños Rivero, M | 1 |
| Turégano García, Á | 1 |
| Martín Sánchez, AM | 1 |
| Flieger, D | 1 |
| Klassert, C | 1 |
| Hainke, S | 1 |
| Keller, R | 1 |
| Kleinschmidt, R | 1 |
| Fischbach, W | 1 |
1 trial available for ofloxacin and Colorectal Neoplasms
| Article | Year |
|---|---|
Phase II clinical trial for prevention of delayed diarrhea with cholestyramine/levofloxacin in the second-line treatment with irinotecan biweekly in patients with metastatic colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antidiarrheals; Camptothecin; Cholestyramine Resin; Colorectal Neopl | 2007 |
2 other studies available for ofloxacin and Colorectal Neoplasms
| Article | Year |
|---|---|
Magneto-Fluorescent Mesoporous Nanocarriers for the Dual-Delivery of Ofloxacin and Doxorubicin to Tackle Opportunistic Bacterial Infections in Colorectal Cancer.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Colorectal Neoplasms; Doxorubicin; Drug Carriers; Drug | 2022 |
[Intraperitoneal abscess for Eikenella corrodens].
Topics: Abdominal Abscess; Adenocarcinoma; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacteri | 2011 |